696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial - Choueiri, T.K.; Powles, T.; Burotto, M.; Bourlon, M.T.; Zurawski, B.; Oyervides Juárez, Víctor Manuel; Hsieh, J.J.; Basso, U.; Shah, A.Y.; Suarez, C.; Hamzaj, A.; Barrios, C.H.; et al. (Kluwer university press, 2020)